|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0001554,
umls-concept:C0001688,
umls-concept:C0030705,
umls-concept:C0033522,
umls-concept:C0087111,
umls-concept:C0221912,
umls-concept:C0678257,
umls-concept:C0879626,
umls-concept:C0995188,
umls-concept:C1135135,
umls-concept:C1273870
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2006-8-15
|
|
pubmed:abstractText |
Drugs such as cetuximab or erlotinib, which inhibit the epidermal growth factor receptor, are increasingly being used in treatment of solid tumors. This has led to the appearance of new secondary effects.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Sep
|
|
pubmed:issn |
1097-6787
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
55
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
429-37
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:16908348-Aged,
pubmed-meshheading:16908348-Antibodies, Monoclonal,
pubmed-meshheading:16908348-Antineoplastic Agents,
pubmed-meshheading:16908348-Drug Eruptions,
pubmed-meshheading:16908348-Female,
pubmed-meshheading:16908348-Humans,
pubmed-meshheading:16908348-Male,
pubmed-meshheading:16908348-Middle Aged,
pubmed-meshheading:16908348-Neoplasms,
pubmed-meshheading:16908348-Prospective Studies,
pubmed-meshheading:16908348-Protein Kinase Inhibitors,
pubmed-meshheading:16908348-Quinazolines,
pubmed-meshheading:16908348-Receptor, Epidermal Growth Factor
|
|
pubmed:year |
2006
|
|
pubmed:articleTitle |
Description and management of cutaneous side effects during cetuximab or erlotinib treatments: a prospective study of 30 patients.
|
|
pubmed:affiliation |
Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain. Eroe@santpau.es
|
|
pubmed:publicationType |
Journal Article
|
